News | Heart Failure | September 21, 2017

MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017

New positive data on secondary and exploratory endpoints consistent with previously reported topline results with mavacamten

MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017

September 21, 2017 — MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study were presented at the Heart Failure Society of America (HFSA) 21st Annual Scientific Meeting, Sept. 16-19 in Dallas. PIONEER-HCM was a study of mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy (oHCM) patients.

In an oral presentation as part of the “Big Trials of the Last Year” session at HFSA, Stephen Heitner, M.D., director of the HCM Clinic at Oregon Health and Science University’s Knight Cardiovascular Institute, and the lead investigator in the PIONEER-HCM study, presented new time-series plots of individual patient data on the primary endpoint, post-exercise peak left ventricular outflow tract (LVOT) gradient, and time-series plots of mean data on several additional measures, including resting LVOT gradient and resting left ventricular ejection fraction (LVEF) from baseline to week 12. Additional measures of exercise capacity, functional capacity and symptoms were also presented, as well as data on the safety profile of mavacamten.

MyoKardia initially reported positive topline results from this first patient cohort on Aug. 7, 2017, which met the primary endpoint of change in post-exercise peak LVOT gradient from baseline to week 12 as well as key secondary endpoints, including peak oxygen consumption (peak VO2).

The additional results presented by Heitner indicated that mavacamten treatment led to a meaningful reduction, in the first few weeks of treatment, in resting LVOT gradient with a less pronounced reduction in resting LVEF. The rapid reduction in LVOT gradient, observed in 9 out of 10 patients by week 2, supported the addition of a second, low-dose cohort in the PIONEER-HCM trial.

Furthermore, data following the washout period (from week 12 to week 16) were presented for the following measures: post-exercise peak LVOT gradient, resting LVOT gradient, resting LVEF, dyspnea score, NYHA Functional Class and NT-proBNP. For all of these measures, reversion towards baseline values was observed, on average across the cohort, after mavacamten therapy was discontinued.

“These data strengthen the case, initially seen with the release of the topline results, that mavacamten, by targeting the underlying biomechanical defect of the disease, can affect multiple clinically meaningful metrics that characterize the oHCM disease burden,” said Heitner. “On behalf of the investigators, I am pleased to present these additional data showing the concordant and positive effects of mavacamten, with patients feeling better and displaying improvements in exercise capacity.”

In this first patient cohort of PIONEER-HCM, 11 symptomatic, oHCM patients enrolled and 10 completed the study. Patients were treated with a 10 mg or 15 mg starting daily dose of mavacamten for 12 weeks, followed by a four-week washout phase. In this first cohort, patients were required to discontinue background therapy including beta blockers.

The following table summarizes the baseline characteristics of the 11 patients enrolled in the first cohort of PIONEER-HCM:

Age, years; mean (min-max)
56 (22-70)

Sex, % male
64

NYHA Functional Class
64% Class II; 36% Class III

History of Paroxysmal Atrial Fibrillation
1

History of Septal Myectomy
1

Previous Background Beta Blocker Therapy, Discontinued Prior to Study Start per Protocol
9

Resting LVEF, %;mean ± SD
70 ± 7.0

Exercise LVEF, %; mean ± SD
76 ± 7.8

Resting LVOT Gradient, mmHg; mean ± SD
68 ± 34.4

Post-Exercise Peak LVOT Gradient, mmHG; mean ± SD
125 ± 60.0

Peak VO2, mL/kg/min; mean ± SD
20.7 ± 7.44

Impact of mavacamten on additional secondary and exploratory endpoints

  • Time-series of mean resting LVOT gradient and mean LVEF were reported today for the first time, showing concordance with data previously reported. Resting LVOT gradient was reduced to 14 ± 24.6 mmHg (mean ± SD) at week 12 from a baseline value of 68 ± 34.4 mmHg. Resting LVEF was reduced to 55 ± 13.1% at week 12 from a baseline value of 70 ± 7.0%.
     
  • A mean time-series plot of dyspnea numerical rating scale (NRS), a common measure of patient symptoms, was also reported. At week 12, patients achieved an average dyspnea NRS of 1.7 ± 1.8 compared to a baseline of 4.9 ± 1.6 (p=0.002).
     
  • Furthermore, additional CPET measures of exercise capacity, including VE/VCO2 and circulatory power, also showed similar trends as previously reported data.

 

Safety overview

  • Mavacamten was generally well-tolerated in this first patient cohort of PIONEER-HCM. As previously reported, one patient experienced a serious adverse event due to a recurrence of atrial fibrillation and elected to stop study drug at week 4.
     
  • All other adverse events (AEs) were mild to moderate. A majority of AEs were deemed unrelated to study drug. Of these non-serious AEs, the most common observations (defined as three or more events) in this cohort were: headache (4), reduction in ejection fraction (3) and nausea (3). None of these patients with an adverse event report of reduction in ejection fraction had symptoms of decompensated heart failure.
     
  • Finally, a time-series plot of mean NT-proBNP, a biomarker commonly used to track severity of heart failure, was presented, providing additional support for the favorable safety profile observed.

MyoKardia intends to discuss the mavacamten clinical development plan in an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and seek feedback on the potential for EXPLORER-HCM, its next study of mavacamten in symptomatic oHCM, to be a pivotal study with peak VO2 as the primary endpoint. The key inclusion and exclusion criteria for EXPLORER-HCM are anticipated to be similar to those for PIONEER-HCM. 

For more information: www.myokardia.com

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo